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Medical Statistics) and actual drug prices (Rote Liste,
2003) were used to calculate total costs of CSA treatment
in Germany from the German payers perspective for the
year 2003. (Discounts from the whole saler, pharmaceu-
tical industry, retail pharmacies and patients copayments
were taken into consideration). RESULTS: Total efﬁcacy
as stated by the physicians depends on CSEA and was
seen between 53% and 76%. The total efﬁcacy experi-
enced by the physicians weighted with 2002 sales was
71%. Total sales in 2003 are €995.6 million. In total €1.4
billion must be invested for completely (100%) reaching
the LDL-C goal of the European treatment guideline.
CONCLUSION: Although it is stated by Klose and
Schwabe (2003) that nearly €2.million of estimated €2.8
million patients could be treated sufﬁciently with CSEA
the results of our study indicate that the investment for a
sufﬁcient treatment must be higher or the treatment itself
must be improved by more efﬁcient drugs.
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OBJECTIVES: To evaluate the total treatment cost 
and cost-effectiveness of three alternative treatments for
patients with acute myocardial infarction from the per-
spective of the Greek NHS. METHODS: A systematic
review of the literature was conducted to identify RCTs
evaluating the treatments considered. Outcomes include
all major health events associated with an AMI. Trial data
we extracted and used to populate a decision analytic
model. Data from long term studies were used to extrap-
olate 30-day and one-year data to end of lifetime. The
model also accounts for patient risk croup, in regards to
age, sex, time-to- treatment, etc. The database of a large
University Hospital was analyzed to estimate in-patient
and outpatient costs associated with various groups of
patients. Simulation was used to test the robustness of the
results. RESULTS: Outcome data primarily come from
GUSTO III and ASSENT 2 and their follow ups. For the
average patient life time costs on alteplase, reteplase 
and tenecteplase were similar, at €24,205, €24,308, and
€24,488 respectively. Average survival was 8.2221,
8.2110, and 8.2919 years respectively. Tenecteplase has
marginally higher cost and outcomes. Alteplase and ten-
ecteplase dominate the second arm and the incremental-
cost-per-life-year-saved of tenecteplase over alteplase is
about €4000, and for that reason it should be preferred
on the basis of its very cost-effective ratio. These results
are based the point estimates and in general terms they
also hold true when simulation is employed. CONCLU-
SIONS: The cost of the original treatment is only a minor
component of the total life time treatment cost of AMI
patients. The treatments evaluated here have similar sur-
vival and different health event proﬁles, but despite that
they are characterized by similar total treatment costs, so
that it is difﬁcult to distinguish between them. If anything,
tenecteplase is characterized by a marginally better cost-
effectiveness ratio.
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OBJECTIVES: Statin therapy reduces the rate of coro-
nary heart disease (CHD), but high costs in combination
with a large population eligible for treatment ask for pri-
oritizing. One of the tools of priority setting is cost-
effectiveness analysis (CEA). Even though all trials agree
on the size of the beneﬁt, CEA of statins report contra-
dictory results. We reviewed CEA comparing statins with
no pharmacological therapy and sought to synthesize cost
effectiveness ratios (CER) for categories of risk of CHD
and age. The level of heterogeneity among CER and its
potential sources were evaluated. METHODS: Systematic
review of the published statin CEA in Medline, the British
National Health Service Economic Evaluation database
and authors’ reference lists. Outcomes were standardized
by inﬂation and currency and stratiﬁed by risk and age.
CER under US$20,000 per life year saved were “cheap”,
over US$40,000 were “expensive” and in between were
“moderate”. Sources of heterogeneity in the outcomes
after stratiﬁcation were analyzed using a regression
model. RESULTS: Twenty-four studies were included,
yielding 216 CER. The range of CER varied 10-fold
(savings to $489,394). Disagreement existed at levels of
risk lower than 4%. After adjusting for risk in the regres-
sion model, the only signiﬁcant variable was funding
source. CONCLUSIONS: Statin therapy is cheap for high
levels of risk, but discrepancies exist at lower levels.
Scarce evidence exists for younger and older ages (<45,
>65). Competing interests between pharmaceutical com-
panies wanting to sell more and governments wanting to
spend less may have strong impact on the results. Clear
guidelines for CEA could reduce their vulnerability to bias
and assure reproducibility.
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